Document Detail

Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
MedLine Citation:
PMID:  19346662     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEI) reduce the mortality in the chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor blockers (ARB) have been reported. However, these effects of ARB have not yet been established in Japanese patients. A multicenter randomized study was designed for the present study to examine the effect of valsartan as compared to that of ACEI against left ventricular dysfunction after MI. METHODS AND RESULTS: Patients with acute MI were randomly allocated to either the valsartan group (n=120; mean age 63 +/-1.0) or the ACEI group (n=121; mean age 62.9 +/-1.0) and followed up until 6 months. Left ventriculography was performed during hospital admission and at 6 months. The blood pressure was similar in the 2 groups throughout the study. The incidences of cardiovascular events and target vessel revascularization were similar, although that of adverse events was significantly higher in the ACEI (12.4%) than in the valsartan group (3.3%; P<0.05). There were no differences in left ventricular ejection fraction and left ventricular end-diastolic volume index between the groups. CONCLUSIONS: Valsartan exhibits similar efficacy effective to that of ACEI in preventing left ventricular dysfunction in Japanese patients with acute MI, and is, in addition, better tolerated than ACEI.
Hiroshi Suzuki; Eiichi Geshi; Shuji Nanjyo; Hajime Nakano; Jyunichi Yamazaki; Naoki Sato; Keiji Tanaka; Teruo Takano; Hidenori Yagi; Takahiro Shibata; Seibu Mochizuki; Takashi Katagiri
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2009-04-02
Journal Detail:
Title:  Circulation journal : official journal of the Japanese Circulation Society     Volume:  73     ISSN:  1346-9843     ISO Abbreviation:  Circ. J.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-24     Completed Date:  2009-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101137683     Medline TA:  Circ J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  918-24     Citation Subset:  IM    
Department of Medicine, Division of Cardiology, Showa University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / adverse effects,  therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Asian Continental Ancestry Group
Disease Progression
Middle Aged
Myocardial Infarction / complications,  drug therapy*,  ethnology
Stroke Volume / drug effects
Tetrazoles / adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Valine / adverse effects,  analogs & derivatives*,  therapeutic use
Ventricular Dysfunction, Left / ethnology,  etiology,  prevention & control*
Ventricular Remodeling / drug effects
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine
Comment In:
Circ J. 2009 May;73(5):820-1   [PMID:  19390158 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of decreased renal function on coagulation and fibrinolysis in patients with non-valvular atr...
Next Document:  Effects of Long-Term Intravenous Administration of Adrenomedullin (AM) Plus hANP Therapy in Acute De...